ライフサイエンスコーパス: major adverse cardiac event

1 myocardial infarction, and their composite, major adverse cardiac events).

2 , and mortality) into a composite end point (major adverse cardiac events).

3 The primary safety end point was a major adverse cardiac event.

4 1 years, 2183 (23.9%) patients experienced a major adverse cardiac event.

5 adverse events, serious adverse events, and major adverse cardiac event.

6 e followed for 30 days for the occurrence of major adverse cardiac events.

7 s for improved prediction of 1-year death or major adverse cardiac events.

8 ve cardiac troponin T with the occurrence of major adverse cardiac events.

9 rty-day periprocedural mortality and rate of major adverse cardiac events.

10 endpoint of the study was the occurrence of major adverse cardiac events.

11 ependently associated with the occurrence of major adverse cardiac events.

12 ned by CMR was significantly associated with major adverse cardiac events.

13 end point of the study was the occurrence of major adverse cardiac events.

14 n over clinical risk score for prediction of major adverse cardiac events.

15 ot an independent predictor of mortality and major adverse cardiac events.

16 myocardial infarction, stent thrombosis, and major adverse cardiac events.

17 we contacted patients by telephone to assess major adverse cardiac events.

18 emia-driven unplanned revascularization, and major adverse cardiac events.

19 objectives included platelet aggregation and major adverse cardiac events.

20 aspirin alone at reducing short or long-term major adverse cardiac events.

21 o FFR with respect to the rate of subsequent major adverse cardiac events.

22 an independent prognostic imaging marker of major adverse cardiac events.

23 oronary intervention in reducing the risk of major adverse cardiac events.

24 e of binary in-stent restenosis and 12-month major adverse cardiac events.

25 mbosis, target lesion revascularization, and major adverse cardiac events.

26 ded changes in LV volumes, infarct size, and major adverse cardiac events.

27 There was no difference in major adverse cardiac events (1.8% versus 2.3%; P=0.75)

28 Mortality (0% vs. 1.9%, p = 0.06) and major adverse cardiac events (1.8% vs. 2.3%, p = 0.75) a

29 r, and resting LV function (hazard ratio for major adverse cardiac events = 1.36, 95% confidence inte

30 s (8.7% versus 19.12%; P=0.078) and 12-month major adverse cardiac events (10.29% versus 19.12%; P=0.

31 ation (TLR) (3.9% vs. 16.0%, p < 0.0001) and major adverse cardiac events (11.1 vs. 21.7%, p = 0.002)

32 rtality rate (9.3% versus 20.1%; P<0.01) and major adverse cardiac events (13.0% versus 26.4%; P<0.01

33 f 382 [3.4%] vs 29 of 365 [7.9%]; P = .007), major adverse cardiac events (15 of 382 [3.9%] vs 30 of

34 larizations (2.4% versus 5.8%, P=0.002), and major adverse cardiac events (2.4% versus 6.3%, P=0.0009

35 er mortality (8 [7.7%] versus 12 [1.9%]) and major adverse cardiac events (21 [20.2%] versus 31 [4.9%

36 -year follow-up, there was no difference for major adverse cardiac events (25.3 versus 25.4%; P=0.683

37 5% CI, 0.36-1.00; P = .046); and for overall major adverse cardiac events, 39 (20.1%) vs 22 (11.5%) (

38 5%-0.99%]) and a 1.21-fold increased risk of major adverse cardiac events (4.24% vs 3.50%; absolute i

39 ; 95% confidence interval: 0.46 to 1.66) and major adverse cardiac events (4.8% vs. 5.5%; adjusted ha

40 undergoing stress-CMR showed a lower rate of major adverse cardiac events (5% versus 10%; P<0.010) an

41 vs. 2.5%, OR 1.83 [95% CI 1.43 to 2.34]) and major adverse cardiac events (5.1% vs. 3.3%, OR 1.54 [95

42 s associated with a reduction in the risk of major adverse cardiac events (6.5% versus 10.3%; odds ra

43 , 3%, 2%, and 0.7%, p < 0.001), and rates of major adverse cardiac events (8%, 5%, 3%, and 4%, p = 0.

44 confidence interval [CI], 1.32-3.18) and of major adverse cardiac events (88/681 events [13.6%] in R

45 At 2 years, there was no difference in major adverse cardiac events (98.0% for ETT and 97.7% fo

46 all-cause death, all-cause readmissions, and major adverse cardiac events (a composite of all-cause d

47 Primary end point was the rate of major adverse cardiac events, a composite of cardiac dea

48 The primary end point was major adverse cardiac events, a composite of cardiac dea

49 es in terms of major adverse cardiac events (major adverse cardiac events, a composite of death, myoc

50 The coprimary end points were the rates of major adverse cardiac events--a composite of death, myoc

51 he primary end point was the occurrence of a major adverse cardiac event: a composite of death, reinf

52 ntly associated with a higher 2-year risk of major adverse cardiac events (adjusted hazard ratio, 2.3

53 raction between HPR and SVG PCI in regard to major adverse cardiac events (adjusted Pinteraction=0.99

54 hin 12 months, 14 patients (7.6%) suffered a major adverse cardiac event after sevoflurane and 17 (8.

55 There were no major adverse cardiac events after discharge in either g

56 The cumulative risk of major adverse cardiac events after maximum follow-up was

57 e diagnostic strategies had no difference in major adverse cardiac events after normal index testing

58 , and total mortality or hospitalization for major adverse cardiac events (aHR: 0.30; 95% CI: 0.12 to

59 .09), total mortality or hospitalization for major adverse cardiac events (aHR: 2.02; 95% CI: 1.32 to

60 8 years to determine medication history and major adverse cardiac events: all-cause mortality, nonfa

61 propriate, an abnormal MPI failed to predict major adverse cardiac events, although it was associated

62 flow </=1, nitrite reduced infarct size and major adverse cardiac event and improved myocardial salv

63 Compared with the prestent era, in-hospital major adverse cardiac events and 1-year target vessel re

64 OPCAB is associated with fewer major adverse cardiac events and benefits women dispropo

65 ; P<0.0001) with low negative event rates of major adverse cardiac events and cardiac death (0.6% and

66 an experienced significantly higher rates of major adverse cardiac events and coronary revascularizat

67 0.8% vs. 5.9%; p = 0.007), had more nonfatal major adverse cardiac events and/or D/GL (45.8% vs. 16.8

68 primary efficacy composite end point (30-day major adverse cardiac events) and of the secondary end p

69 ed risks of 30-day all-cause readmissions or major adverse cardiac events, and 1-year mortality, all-

70 (61%) evaluated mortality, 7 (30%) evaluated major adverse cardiac events, and 2 (9%) evaluated angio

71 were postoperative NT-proBNP concentrations, major adverse cardiac events, and delirium.

72 te marker for subsequent mortality, nonfatal major adverse cardiac events, and development of angiogr

73 eart Failure Questionnaire, 6-min walk test, major adverse cardiac events, and immune biomarkers.

74 P, procedural and in-hospital events, 30-day major adverse cardiac events, and target vessel revascul

75 levation myocardial infarction patients with major adverse cardiac events as compared with those with

76 Importantly, the risk for major adverse cardiac events associated with FFR/CFVR di

77 index (P=0.05) and reduction in [corrected] major adverse cardiac event at 1 year (2.6% versus 15.8%

78 at 1 year (HR, 1.24; 95% CI, 1.14-1.36), and major adverse cardiac events at 1 year (HR, 1.21; 95% CI

79 resulted in a lower rate of the composite of major adverse cardiac events at 1 year among patients wi

80 Major adverse cardiac events at 1 year occurred in 13.2%

81 Major adverse cardiac events at 1 year occurred in 24 pa

82 Major adverse cardiac events at 1 year were higher with

83 The primary endpoint was major adverse cardiac events at 1 year, and the data for

84 t differ in postoperative NT-proBNP release, major adverse cardiac events at 1 year, or delirium.

85 V thrombus was independently associated with major adverse cardiac events at 1-year follow-up.

86 dependently associated with the incidence of major adverse cardiac events at 12 months (hazard ratio,

87 ization strategy with respect to the rate of major adverse cardiac events at 12 months.

88 Major adverse cardiac events at 3 years were significant

89 The incidence of major adverse cardiac events at 30 days was 11.2% for th

90 Incidence of major adverse cardiac events at 30 days was 25% with aco

91 piration system, results in similar rates of major adverse cardiac events at 30 days.

92 ity at 6 weeks and 1.8 percentage points for major adverse cardiac events at 9 months.

93 ery with respect to mortality at 6 weeks and major adverse cardiac events at 9 months.

94 avenous abciximab and found similar rates of major adverse cardiac events at 90 days with significant

95 Higher volume was associated with improved major adverse cardiac events at every threshold, regardl

96 determine whether the 1-year differences in major adverse cardiac event between a stent eluting biol

97 hazard curves for target vessel failure and major adverse cardiac events between 1 and 2 years evide

98 No difference was observed in major adverse cardiac events between sexes and ED strate

99 The adjusted hazard ratios for major adverse cardiac events between the highest and low

100 ulted in significant reductions in composite major adverse cardiac events both at 9 months (4.6% vs 8

101 1-year mortality, all-cause readmissions, or major adverse cardiac events, but these were attenuated

102 3% (11.3% vs. 24%, p < 0.004), and composite major adverse cardiac events by 44% (15.6% vs. 27.7%, p

103 10.0% versus 19.4%, P<0.0001), and composite major adverse cardiac events by 49% (10.8% versus 20.0%,

104 y artery disease) improved discrimination of major adverse cardiac events (C statistic, 0.81-0.86; P=

105 Major adverse cardiac events (cardiac death, MI, or repe

106 0.48 to 0.98; P=0.04) and a 45% reduction in major adverse cardiac events (cardiac death, myocardial

107 tional secondary end point was evaluation of major adverse cardiac events (cardiac death, myocardial

108 ciated with increased risk for postdischarge major adverse cardiac events (cardiac death, myocardial

109 The primary outcome was major adverse cardiac events (cardiac death, recurrent m

110 was performed to document the occurrence of major adverse cardiac events: cardiac death, myocardial

111 ted to medical history and the occurrence of major adverse cardiac events (cardiovascular death, myoc

112 icated target lesion revascularization), and major adverse cardiac events (combination of all-cause d

113 ial Infarction grade 3 flow and freedom from major adverse cardiac events (composite of death, Q-wave

114 Endpoints were major adverse cardiac events (composite of death, reinfa

115 -cause mortality, myocardial infarction, and major adverse cardiac events (comprising mortality, myoc

116 Major adverse cardiac events could be predicted using a

117 Estimated 10-year rate of major adverse cardiac events (death, heart failure, myoc

118 S presentations had an independent effect on major adverse cardiac events (death, MI, and re-target l

119 primary outcome was 1-year composite rate of major adverse cardiac events (death, myocardial infarcti

120 Major adverse cardiac events (death, myocardial infarcti

121 , index length of stay, early discharge, and major adverse cardiac events (death, myocardial infarcti

122 The primary end point was major adverse cardiac events defined as all-cause mortal

123 edures, cumulative effective radiation dose, major adverse cardiac events, defined as a composite end

124 he primary end point was 2-year incidence of major adverse cardiac events, defined as CAD death or ho

125 sulting in a significant reduction in 1-year major adverse cardiac events, driven by a lower incidenc

126 or rates of target vessel failure, and fewer major adverse cardiac events during 1 year of follow-up.

127 successful procedure without device-related major adverse cardiac events during 6 months.

128 drome (ACS) during index hospitalization and major adverse cardiac events during 6-month follow-up.

129 The rate of major adverse cardiac events during a median follow-up o

130 phil cationic protein serum levels predicted major adverse cardiac events during follow-up (odds rati

131 procedure and hospitalization and costs for major adverse cardiac events during follow-up.

132 rdiac death, myocardial infarction (MI), and major adverse cardiac events during the follow-up period

133 To assess the rates of major adverse cardiac events during the index admission

134 mid-1980s, and the current annual risk of a major adverse cardiac event following PCI is 5% to 7%.

135 ed PCI resulted in a significant decrease of major adverse cardiac events for up to 2 years after the

136 973 CABG and 2255 PCI patients, Kaplan-Meier major adverse cardiac event-free survival curves demonst

137 ical therapy as a more powerful predictor of major adverse cardiac event-free survival than choice of

138 ng nonadherent patients, CABG affords better major adverse cardiac event-free survival.

139 erve was a powerful incremental predictor of major adverse cardiac events (hazard ratio, 0.80 [95% co

140 sus nondiabetic patients had higher risks of major adverse cardiac events (hazard ratio, 1.25; 95% co

141 % DS) was an independent predictor of 1-year major adverse cardiac events (hazard ratio, 1.36; 95% co

142 ed as a significant independent predictor of major adverse cardiac events (hazard ratio, 4.41 [confid

143 dependent predictor of lower rates of 30-day major adverse cardiac events (hazard ratio: 0.72 [95% co

144 hemia demonstrated a strong association with major adverse cardiac events (hazard ratio=14.66; P<0.00

145 atistically significant predictor of time to major adverse cardiac events (hazard-ratio, 3.36; 95% co

146 s associated with higher incidence of 1-year major adverse cardiac event (hazards ratio=2.2; P=0.02).

147 49-0.88; P=0.004), and composite adjudicated major adverse cardiac events (ie, cardiac death, myocard

148 mortality, cardiac events, and the composite major adverse cardiac events (ie, death, acute myocardia

149 There are no published data on short-term major adverse cardiac events in hospitalized patients un

150 major hemorrhage, MI, stent thrombosis, and major adverse cardiac events in patients randomized to p

151 Eptifibatide reduces major adverse cardiac events in patients with acute coro

152 l stents in de novo coronary lesions reduces major adverse cardiac events in patients with and withou

153 of care and safety, defined as freedom from major adverse cardiac events in patients with normal ind

154 , which results from carbamylation, predicts major adverse cardiac events in patients with normal ren

155 yocardial infarction, as well as the risk of major adverse cardiac events in the ensuing 30-day and 6

156 Freedom from major adverse cardiac events in the highest (effective)

157 Risks of SCAD recurrence and major adverse cardiac events in the long term emphasize

158 It found a 17% overall reduction in major adverse cardiac events in the statin-treated group

159 Major adverse cardiac events included death, myocardial

160 MAO) levels in blood predict future risk for major adverse cardiac events including myocardial infarc

161 We assessed major adverse cardiac events, including cardiac death, m

162 Major adverse cardiac events, including cardiac death, n

163 larization (23.5% versus 54.6%; P<0.001) and major adverse cardiac events, including target vessel re

164 Mortality and major adverse cardiac events increase as operator volume

165 iac death or nonfatal myocardial infarction (major adverse cardiac events) incremental to clinical ri

166 brinolysis inhibitor, and lipoprotein(a) for major adverse cardiac events is highly variable and conf

167 Recently, major adverse cardiac event (MACE) and mortality risk ca

168 This study recorded the occurrence of a major adverse cardiac event (MACE) assessed as the compo

169 uring hospitalization (primary outcome) or a major adverse cardiac event (MACE) or death within 30 da

170 the DPP-4 inhibitor alogliptin to placebo on major adverse cardiac event (MACE) rates in patients wit

171 The primary endpoint was a major adverse cardiac event (MACE) within 30 days.

172 The primary endpoint was major adverse cardiac event (MACE) within 30 days.

173 italization were followed for instances of a major adverse cardiac event (MACE), such as a myocardial

174 n, new cardiac tumour formation on MRI, or a major adverse cardiac event (MACE; composite of death an

175 h, stroke, myocardial infarction or combined major adverse cardiac events (MACE = death or stroke or

176 Secondary outcomes included major adverse cardiac events (MACE) (any of the 3 primar

177 The primary endpoint was the composite of major adverse cardiac events (MACE) (cardiovascular deat

178 compare estimates for revascularization and major adverse cardiac events (MACE) (death, myocardial i

179 Endpoints were adjudicated major adverse cardiac events (MACE) (death, myocardial i

180 % confidence interval [CI]: 0.74 to 1.34) or major adverse cardiac events (MACE) (death, readmission

181 We compared death and major adverse cardiac events (MACE) (death, reinfarction

182 etween gender and sex with recurrent ACS and major adverse cardiac events (MACE) (e.g., ACS, cardiac

183 nventional primary PCI (18 trials, n=3,936): Major adverse cardiac events (MACE) (risk ratio [RR]: 0.

184 sures were cardiac death, general mortality, major adverse cardiac events (MACE) (severe angina, myoc

185 etween timing of surgery and stent type with major adverse cardiac events (MACE) adjusting for patien

186 ictors and built the best overall models for major adverse cardiac events (MACE) and cardiac mortalit

187 he extended algorithm) for predicting 30-day major adverse cardiac events (MACE) and to compare it wi

188 Primary endpoint was major adverse cardiac events (MACE) at 1 year consisting

189 The ability of each score to predict major adverse cardiac events (MACE) at 1 year was compar

190 variants, platelet function, and the risk of major adverse cardiac events (MACE) at 2 years was asses

191 The primary effectiveness outcome was 2-year major adverse cardiac events (MACE) comprising death, re

192 All patients were followed up for major adverse cardiac events (MACE) defined as a composi

193 69) and the combined endpoints (n = 116) of major adverse cardiac events (MACE) defined as cardiovas

194 lized with pneumococcal pneumonia experience major adverse cardiac events (MACE) during or after pneu

195 eneity and validity of composite end points, major adverse cardiac events (MACE) in particular, in ca

196 trated great potential for the prediction of major adverse cardiac events (MACE) in ST-segment-elevat

197 The primary endpoint was a composite of major adverse cardiac events (MACE) including cardiac de

198 In-hospital major adverse cardiac events (MACE) including myocardial

199 At one year, major adverse cardiac events (MACE) occurred in 13.5% of

200 d to determine the annualized probability of major adverse cardiac events (MACE) of cardiac death or

201 imary efficacy endpoint was the incidence of major adverse cardiac events (MACE) up to 30 days.

202 Major adverse cardiac events (MACE) were assessed in the

203 Major adverse cardiac events (MACE) were defined as deat

204 y intervention has a 15% to 20% incidence of major adverse cardiac events (MACE) within 30 days.

205 Major adverse cardiac events (MACE), comprising signific

206 Primary end point was 8-month major adverse cardiac events (MACE), defined as adjudica

207 We recorded the occurrence of major adverse cardiac events (MACE), defined as deaths f

208 sion (TMP) blush, ST-segment resolution, and major adverse cardiac events (MACE), defined as the occu

209 y (in-hospital and 30-day) and late (1-year) major adverse cardiac events (MACE), including cardiac d

210 Primary endpoint was a composite of major adverse cardiac events (MACE), including cardiac d

211 Major bleeding and major adverse cardiac events (MACE), including death, my

212 The primary end point was 1-year major adverse cardiac events (MACE), which included deat

213 h unsuccessful PCI in both groups for 30-day major adverse cardiac events (MACE).

214 - or everolimus-eluting stents) for reducing major adverse cardiac events (MACE).

215 e an important risk factor for postoperative major adverse cardiac events (MACE).

216 ause mortality, cardiovascular mortality and major adverse cardiac events (MACE).

217 y endpoints were in-stent binary restenosis, major adverse cardiac events (MACE: cardiac death, myoca

218 tion (TVR; 16.7% versus 12.1%, P=0.006), and major adverse cardiac events (MACE; 23.9% versus 15.3%,

219 Secondary end points were major adverse cardiac events (MACE; a composite of all-c

220 Secondary efficacy end points included major adverse cardiac events (MACE; cardiac death, myoca

221 enosis, target lesion revascularization, and major adverse cardiac events (MACE; death, myocardial in

222 The incidence of major adverse cardiac events (MACE; the combined end poi

223 arction (MI)/revascularization/stroke (i.e., major adverse cardiac events [MACE]) and secondary endpo

224 ssay is associated with reduced incidence of major adverse cardiac events (MACEs) and cardiovascular

225 The primary end points were major adverse cardiac events (MACEs) defined as cardiova

226 Evaluation for major adverse cardiac events (MACEs) occurred at 30 days

227 Major adverse cardiac events (MACEs) were defined as lat

228 pain according to their short-term risk for major adverse cardiac events (MACEs), but its effect on

229 All-cause mortality (ACM) and documented major adverse cardiac events (MACEs)-myocardial infarcti

230 Clinical outcomes in terms of major adverse cardiac events (major adverse cardiac even

231 l as the composite major adverse events (ie, major adverse cardiac events, major bleeding, or thrombo

232 The primary outcome was 30-day major adverse cardiac events (mortality, readmission for

233 nt cardiovascular disease (CVD) and incident major adverse cardiac events (myocardial infarction, str

234 PON1 activity with prevalent CVD and future major adverse cardiac events (myocardial infarction, str

235 s at presentation also predicted the risk of major adverse cardiac events (myocardial infarction, the

236 Patients in whom major adverse cardiac events occurred had significantly

237 Major adverse cardiac events occurred in 1.1% and 4.2% o

238 Major adverse cardiac events occurred in 173 diabetics (

239 After 5 years, major adverse cardiac events occurred in 31% of patients

240 CI, -0.76 to -0.21) and a decreased risk of major adverse cardiac events (odds ratio, 0.49; 95% CI,

241 pectively followed up for 27+/-10 months for major adverse cardiac events of death, death or myocardi

242 gical findings do not directly contribute to major adverse cardiac event outcomes.

243 -cause death and heart failure (P=0.004) and major adverse cardiac events (P=0.013).

244 e of anemia is associated with higher 30-day major adverse cardiac events, post-PCI peak troponin and

245 Overall, the 5-year major adverse cardiac event rate was 11.0%, without any

246 ng-term follow-up was 3.1 years, and overall major adverse cardiac event rate was 19.9% (death rate:

247 Two-year major adverse cardiac event rate was 6.8% without any sc

248 The 1-year major adverse cardiac event rate was increased among pat

249 The major adverse cardiac event rate was lower, too, in the

250 At 5 years, the major adverse cardiac event rate was significantly reduc

251 was associated with significantly increased major adverse cardiac events rate throughout 10 years of

252 ithin 6 hours, there was no change in 30-day major adverse cardiac event rates (0.52% versus 0.44%; P

253 Major adverse cardiac event rates at 2 years among those

254 E had higher in-hospital, 30-day, and 1-year major adverse cardiac event rates than patients without

255 One- and 6-month major adverse cardiac event rates were low and similar i

256 Major adverse cardiac event rates were similar (13.0% vs

257 jury with subsequent significantly increased major adverse cardiac event rates.

258 able lumen dimensions and low restenosis and major adverse cardiac event rates.

259 Target lesion revascularization and major adverse cardiac events rates during follow-up were

260 At 3 mo, 96 patients were free of major adverse cardiac events, repeat hospital chest pain

261 endpoints were composite upper GI events and major adverse cardiac events, respectively.

262 For association with major adverse cardiac events, RevPD was the strongest mu

263 ated no significant differences in composite major adverse cardiac event scores at each time point up

264 SR presentation has an independent effect on major adverse cardiac events, suggesting that ISR remain

265 The rate of 30-day major adverse cardiac events suggests that early adminis

266 0 years) showed no significant difference in major adverse cardiac events (target vessel revasculariz

267 ho had OPCAB had lower risk-adjusted odds of major adverse cardiac events than their racial counterpa

268 s: 6-week mortality and 9-month incidence of major adverse cardiac events (the composite of death, Q-

269 .43; 95% CI, 1.19-1.73) all predicted MACEs [major adverse cardiac events]." These ORs and 95% CIs sh

270 ndary end points included clinical outcomes (major adverse cardiac events), use of healthcare resourc

271 salvage index and a significant reduction in major adverse cardiac event was evident.

272 Ten-year freedom from major adverse cardiac events was also similar for both (

273 Overall occurrence of major adverse cardiac events was significantly less freq

274 The incidence of major adverse cardiac events was significantly lower in

275 At 30 days, the incidence of major adverse cardiac events was similar between the con

276 The incidence of major adverse cardiac events was similar in the 2 groups

277 The impact of ICR on major adverse cardiac events was similar regardless of c

278 Despite treatment, the risk of long-term major adverse cardiac events was substantially increased

279 hazard ratios (95% confidence intervals) for major adverse cardiac events were 0.77 (0.68-0.87), 0.82

280 The 9-month rates of major adverse cardiac events were 12.1% and 11.2% at hos

281 Two-year major adverse cardiac events were 16.9% (retrospectively

282 The rates of major adverse cardiac events were 9.5% in hospitals with

283 Thirty-day major adverse cardiac events were also assessed.

284 its >208 as measured by the VerifyNow assay; major adverse cardiac events were defined as the composi

285 es, and long-term risk of SCAD recurrence or major adverse cardiac events were evaluated.

286 Major adverse cardiac events were numerically lower in t

287 lesions, although significant reductions in major adverse cardiac events were present in all patient

288 Major adverse cardiac events were reduced in diabetic pa

289 In-hospital major adverse cardiac events were significantly lower am

290 were re-vascularized by CABG, mortality and major adverse cardiac events were significantly lower wi

291 er, all-cause mortality and the incidence of major adverse cardiac events were similar in the two gro

292 A was associated with lower risk for midterm major adverse cardiac events when used to supplement SIT

293 vs. 19% and 17%, respectively, p = 0.04) and major adverse cardiac events with increasing stent expan

294 sis in these patients (reduced mortality and major adverse cardiac events) with an increase in major

295 stent thrombosis, myocardial infarction, and major adverse cardiac events within 1 year after DES imp

296 The primary end point was death or major adverse cardiac events within 1 year after surgery

297 ary clinical end point was the occurrence of major adverse cardiac events within 1 year.

298 6% (95% confidence interval, 3.6%-9.5%) had major adverse cardiac events within 30 days of randomiza

299 patients identified for early discharge had major adverse cardiac events within 30 days.

300 point (ZES 17.0% versus EES 16.2%, P=0.61), major adverse cardiac events (ZES 21.9% versus EES 21.6%